Recent experimental studies have found that butyrate regulates CD8+ T cell cytotoxicity through the G protein-coupled receptor 109A (GPR109A) and homologous domain protein homologous box (HOPX) pathway, resulting in enhanced anti-cancer activity against tumor cells in the GC microenvironment (Yu et al., 2024). The gene discussed is CD8A; the disease is cancer.